Skip to main content

Advertisement

SpringerLink
Log in

Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy

  • Topic paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

It is advocated that patients with high-risk non-muscle-invasive bladder cancer (NMIBC) receive an adjuvant course of intravesical Bacille Calmette-Guerin (BCG) as first-line treatment. However, a substantial proportion of patients will ‘fail’ BCG, either early with persistent (refractory) disease or recur late after a long disease-free interval (relapsing). Guideline recommendation in the ‘refractory’ setting is radical cystectomy, but there are situations when extirpative surgery is not feasible due to competing co-morbidity, a patient’s desire for bladder preservation or reluctance to undergo surgery. In this review, we discuss the contemporary management of NMIBC in patients who have failed prior BCG and are not suitable for radical surgery and highlight the potential options available. These options can be categorised as immunotherapy, chemotherapy, device-assisted therapy and combination therapy. However, the current data are still inadequate to formulate definitive recommendations, and data from ongoing trials and maturing studies will give us an insight into whether there is a realistic efficacious second-line treatment for patients who fail intravesical BCG but are not candidates for definitive surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Babjuk M, Oosterlinck W, Sylvester R et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. doi:10.1016/j.eururo.2011.03.017

  2. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964

    Google Scholar 

  3. Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247

    Article  PubMed  Google Scholar 

  4. Thalmann GN, Markwalder R, Shahin O et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70

    Article  PubMed  Google Scholar 

  5. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666

    PubMed  CAS  Google Scholar 

  6. Amling CL, Thrasher JB, Frazier HA et al (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151:31

    PubMed  CAS  Google Scholar 

  7. Raj GV, Herr H, Serio AM et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177:1283

    Article  PubMed  Google Scholar 

  8. Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA et al (2004) Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22:290

    Article  PubMed  Google Scholar 

  9. Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 27:347

    Article  PubMed  Google Scholar 

  10. Kulkarni GS, Finelli A, Fleshner NE et al (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4:e284

    Article  PubMed  Google Scholar 

  11. Kulkarni GS, Alibhai SM, Finelli A et al (2009) Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115:5450

    Article  PubMed  Google Scholar 

  12. Lerner SP, Tangen CM, Sucharew H et al (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27:155

    Article  PubMed  Google Scholar 

  13. Herr HW, Dalbagni G (2003) Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 169:1706

    Article  PubMed  CAS  Google Scholar 

  14. Martin FM, Kamat AM (2009) Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9:815

    Article  PubMed  Google Scholar 

  15. Solsona E, Iborra I, Dumont R et al (2000) The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164:685

    Article  PubMed  CAS  Google Scholar 

  16. Nepple KG, Aubert HA, Braasch MR (2009) Combination of BCG and interferon intravesical immunotherapy: an update. World J Urol 27:343

    Article  PubMed  CAS  Google Scholar 

  17. Joudi FN, Smith BJ, O’Donnell MA (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344

    Article  PubMed  CAS  Google Scholar 

  18. Gallagher BL, Joudi FN, Maymi JL (2008) Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology 71:297

    Article  PubMed  Google Scholar 

  19. Nepple KG, Lightfoot AJ, Rosevear HM et al (2010) Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 184:1915

    Article  PubMed  Google Scholar 

  20. Kowalski M, Entwistle J, Cizeau J et al (2010) A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG refractory and BCG-intolerant patients. Drug Des Devel Ther 4:313

    PubMed  CAS  Google Scholar 

  21. Malmstrom PU, Wijkstrom H, Lundholm C (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124

    Article  PubMed  CAS  Google Scholar 

  22. Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729

    Article  PubMed  CAS  Google Scholar 

  23. Dalbagni G, Russo P, Sheinfeld J et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193

    Article  PubMed  CAS  Google Scholar 

  24. Bartoletti R, Cai T, Gacci M et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66:726

    Article  PubMed  Google Scholar 

  25. Di Lorenzo G, Perdona S, Damiano R et al (2010) Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116:1893

    Article  PubMed  CAS  Google Scholar 

  26. Addeo R, Caraglia M, Bellini S et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543

    Article  PubMed  CAS  Google Scholar 

  27. Porena M, Del Zingaro M, Lazzeri M et al (2010) Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. Urol Int 84:23

    Article  PubMed  CAS  Google Scholar 

  28. Bohle A, Leyh H, Frei C et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56:495

    Article  PubMed  Google Scholar 

  29. Gontero P, Cattel L, Paone TC et al (2010) Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int 106:1652

    Article  PubMed  CAS  Google Scholar 

  30. McKiernan JM, Masson P, Murphy AM et al (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075

    Article  PubMed  CAS  Google Scholar 

  31. Laudano MA, Barlow LJ, Murphy AM et al (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134

    Article  PubMed  Google Scholar 

  32. Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331

    Article  PubMed  CAS  Google Scholar 

  33. Chen CH, Yang HJ, Shun CT et al. (2010) A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. Urol Oncol. doi:10.1016/j.urolonc.2010.06.012

  34. Alfred Witjes J, Hendricksen K, Gofrit O et al (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 27:319

    Article  PubMed  CAS  Google Scholar 

  35. Nativ O, Witjes JA, Hendricksen K et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 182:1313

    Article  PubMed  CAS  Google Scholar 

  36. Colombo R, Salonia A, Leib Z et al (2010) Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 107:912

    Article  PubMed  Google Scholar 

  37. Brausi M, Campo B, Pizzocaro G et al (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51:506

    Article  PubMed  CAS  Google Scholar 

  38. Di Stasi SM, Riedl C (2009) Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. World J Urol 27:325

    Article  PubMed  CAS  Google Scholar 

  39. Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777

    Article  PubMed  CAS  Google Scholar 

  40. Waidelich R, Stepp H, Baumgartner R et al (2001) Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165:1904

    Article  PubMed  CAS  Google Scholar 

  41. Berger AP, Steiner H, Stenzl A et al (2003) Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 61:338

    Article  PubMed  Google Scholar 

  42. Lee LS, Thong PS, Olivo M et al (2010) Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy–A potential bladder sparing option for high risk non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 7:213

    Article  PubMed  CAS  Google Scholar 

  43. Van der Meijden AP, Hall RR, Macaluso MP (1996) Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29:19

    Google Scholar 

  44. Oosterlinck W, Kirkali Z, Sylvester R et al (2011) Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus calmette-guerin and with bacillus calmette-guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 59:438

    Article  PubMed  CAS  Google Scholar 

  45. Di Stasi SM, Giannantoni A, Giurioli A et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43

    Article  PubMed  CAS  Google Scholar 

  46. Breyer BN, Whitson JM, Carroll PR et al (2010) Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol 28:510

    Article  PubMed  CAS  Google Scholar 

  47. Chiong E, Esuvaranathan K (2010) New therapies for non-muscle-invasive bladder cancer. World J Urol 28:71

    Article  PubMed  Google Scholar 

  48. Horinaga M, Fukuyama R, Iida M et al. (2010) Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 76:1267 e1261

    Google Scholar 

Download references

Funding source

There was no funding source/sponsorship involved in this report.

Author information

Authors and Affiliations

  1. Academic Department of Urology of la Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, University Paris VI, Faculte de Medicine Pierre et Marie Curie and CeRePP, Centre d’Etudes et de Recherche sur les Pathologies Prostatiques, 47-83 Boulevard de l’Hopital, 75013, Paris, France

    D. R. Yates & M. Rouprêt

Authors
  1. D. R. Yates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Rouprêt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Rouprêt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yates, D.R., Rouprêt, M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol 29, 415–422 (2011). https://doi.org/10.1007/s00345-011-0681-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0681-4

Keywords

Search

Navigation